Our Pipeline

Our platform technology enables the development of broad antimicrobial treatments that has the potential to significantly improve the lives of patients with acute and chronic disease.

Our strategy is to identify targets where our poly-therapeutic can potentially impact patient populations at significant risk of contracting or developing a multi-drug resistant pathogen.

Our current primary asset is in late-stage, pre-clinical testing to treat pulmonary bacterial and fungal disease.

Pulmonary Infections

Drug/Therapeutic Candidate Indication Targets Discovery IND-Enabling Early Clinical
EVQ-218 Cycstic Fibrosis Burkholderia cenocepacia Pseudomonas aeruginosa Stenotrophomonas Late Stage Pre-Clinical
EVQ-218 Bacterial Pneumonia Streptococcus pneumoniae Staphylococcus aureus Streptococcus pyogenes Klebsiella pneumoniae Haemophilus influenzae Early Stage Pre-clinical
EVQ-218 Pulmonary Fungal Infections Candida albicans Aspergillus Early Stage Pre-clinical
EVQ-218 Tuberculosis Mycobacterium tuberculosis Early Stage Pre-clinical

Topical Infections

Drug/Therapeutic Candidate Indication Targets Discovery IND-Enabling Early Clinical
EVQ-221 Cellulitis Group A β-hemolytic streptococcus Streptococcus pneumoniae Late Stage Pre-Clinical
EVQ-221 Staph Skin Infections (e.g. MRSA) Methicillin-resistant Staphylococcus aureus Early Stage Pre-clinical